The Prostate Cancer Blog for Wives and Partners lets you know when new information has been added to our site. Anytime a new page is created — or we feel there is something worth noting — it will be posted here.
Men 66 years or older who treat their (nonmetastatic) prostate cancer with surgery or radiation are more likely to take antidepressant medications than men who do not undergo treatment, according to a new study (Matta et al) that was published online in European Urology. Researchers looked at data from over 12,000 men with prostate cancer (4,952 had surgery, 4,994 had radiation, and 2,136 had surveillance). One year prior to starting treatment, 7.7% of men were prescribed an antidepressant, which increased to 10.5% a year after their treatment. Men also had an increased risk of using antidepressants 5 years after surgery vs men who had no treatment (surveillance). Bear in mind, however, that this was a retrospective study. Retrospective studies look backwards at existing data vs a prospective study that looks for specific outcomes during the course of a study period. Prospective studies typically have fewer potential sources of bias (ie, systematic errors that encourage one outcome over others, which can result in incorrect conclusions). November 7, 2018.
Two drugs used together may be more effective for erectile dysfunction (ED) following the failure of either drug alone, according to an article (Moncada et al, 2018) published in the International Journal of Impotence Research. The clinicians looked at various published articles about two drugs for ED: first-line phosphodiesterease-5 inhibitors (PDE5Is) and alprostadil, which is often a second-line choice by physicians. They suggest that combination therapy may be a treatment option for men to consider following prostatectomy, if they have had a poor response to either drug alone. October 9, 2018.
To those of us who have been watching, it comes as no surprise that a recent study has found that prostate cancer screenings are down, which has led to fewer American men being diagnosed and treated. Part of the decline is no doubt a direct result of the 2012 US Preventive Services Task Force (USPSTF) recommendation against prostate cancer screening. But the numbers started to fall in 2009, according to a new study of 6 million men published in the online edition of CANCER. Specifically, the prostate cancer biopsy rate per 100 men following a PSA test decreased from 1.95 to 1.52 (over the study period, which was from 2008-2014). The incidence of prostate cancer, however, increased from 0.36 to 0.39. The proportion of men with newly diagnosed prostate cancer that underwent local treatment decreased from 69% to 54%. After 2011, both PSA testing and prostate cancer incidence decreased significantly (P < .001). May 29, 2018.
Wives of men with advanced prostate cancer believe that their lives are being undermined by their husband’s illness—and more than half said their own health had suffered—according to a new (but small) study by Danish researchers from Herlev and Gentofte University Hospital. The study included 56 wives of men with metastatic prostate cancer who were undergoing hormone therapy. The researchers selected 8 women (randomly) to conduct focus-group type interviews, which allowed them to express their feelings. Some of the women said they felt isolated and fearful and worried about how their role in life would change as prostate cancer advanced. We have often written that prostate cancer can be as stressful for wives and partners as it is for men and this study supports this belief. But this study does raise some unanswered questions (such as, how old were the women and did the couples have any marriage problems prior to a prostate cancer diagnosis?). The results of the study were presented at the European Association of Urology conference in Copenhagen. March 27, 2018.
Treatment for prostate cancer can be very successful, but it can also result in long-term side effects that can have an impact on not just on men, but on their partners/spouses, too. Partners/spouses are being invited to participate in a new research study to share how they feel about the impact the diagnosis and treatment of prostate cancer has had on them. The researchers are interested in your individual experiences and opinions, including what support has been—or would be—helpful in dealing with your cancer journey. The study is being organized by researchers from Ulster University in Northern Ireland and has been reviewed by the Ulster University Research Ethical Committee. Participation is easy (via a telephone interview) and you will remain anonymous. Your input is wanted and very much needed for the study. For details on how to participate (or if you have any questions), please contact Terri Gilleece via email at: firstname.lastname@example.org. March 2, 2018 [Sponsored post]
There was an interesting onclive.com article this week by Danielle Bucco discussing the results of the 10-year PROTECT study that was published last year (Hamdy et al). In this study, the survival rate of men with localized prostate cancer was not significantly different between 3 groups, including men on active monitoring, men who had external beam radiation therapy, and men who had radical prostatectomy. The primary outcome was prostate-cancer mortality at a median of 10 years of follow-up. Only 1% mortality was reported in each group. What’s interesting about this study is that the researchers recruited 82,429 healthy men aged 50-69 for PSA screening who were counseled about the uncertainties of early prostate cancer treatment before they were even diagnosed. Of that number, 2,664 were eventually diagnosed and 1,643 of those men agreed to be randomized into 1 of the 3 groups. There were 17 prostate-cancer-specific deaths overall (5 in the surgery group, 4 in the radiation group, and 8 in the active monitoring group). Do these results mean that men can safely defer treatment? It is important to note that metastases developed in more men in the active monitoring group (that would be our biggest fear) and higher rates of disease progression were also noted in the same group. When you look at prostate cancer statistics, a lot of men with localized prostate cancer are still alive 10 years after their diagnosis. What we would like to see is what those numbers are like at 20 or 25 years. What remains is the $100,000 question: how long can a man who will ultimately need treatment defer his treatment to preserve his quality of life without fear of cancer progression? In our opinion, we don’t have the right assessment tools to answer that question yet. January 23, 2018.
Recently, there was a very interesting Washington Post article about immunotherapy and the host of strange side effects that some cancer patients are starting to experience, such as myocarditis, type 1 diabetes, and rashes. My husband and I had a potential PSA-on-the-rise scare recently and his urologist mentioned the hope he has for immunotherapy for prostate cancer. This article certainly gave us some pause about whether he would opt for immunotherapy versus traditional hormone depravation therapy. According to the consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group, when it comes to immunotherapy for cancer, “Skin, gut, endocrine, lung and musculoskeletal immune-related adverse events [irAEs] are relatively common, whereas cardiovascular, hematologic, renal, neurologic and ophthalmologic irAEs occur much less frequently." Of course, all therapies have potential side effects. That is why it is wise to always do your own research on possible side effects that are related to a prostate cancer treatment. January 5, 2018
Is vasectomy a risk factor for prostate cancer or not? A vasectomy was not associated with high-grade, advanced stage, or fatal prostate cancer, according to a large review study (Bhindi et al) that analyzed 53 different studies. The study authors reviewed 16 cohort studies of 2,563,519 men, 33 case-controlled studies of 44,536 men, and 4 cross-sectional studies of 12, 098,221 men. The primary outcome was any diagnosis of prostate cancer. Secondary endpoints were high-grade, advanced, and prostate cancer that caused death. They concluded that there was a 0.6% absolute increased risk of prostate cancer associated with vasectomy with a population-attributable fraction of 0.5%. No risk at all? No. Small risk? Apparently. The results were published in JAMA Internal Medicine last month. October 5, 2017.
Should men with early prostate cancer wait to have surgery? Results from a new 20-year study (Wilt et al) showed that early surgery (prostatectomy) did not prolong life and often caused complications, including urinary incontinence, erectile dysfunction, and infection. The study included a total of 731 men with prostate cancer. In the group of men who had surgery (366 men), 223 died. In the non-surgery group (367 men) 245 men died. In a nutshell, the study authors state that there was no significant difference in mortality (death) between the two groups. However, surgery was associated with a lower frequency of treatment for disease progression. There are many factors that can influence results from a study like this (for example, all the men were over 60 years of age) that one should not take this as “proof” that waiting is a viable option. Always discuss your options with your healthcare provider. You can find the study in the New England Journal of Medicine. July 18, 2017.
Circulating tumor cells, along with circulating megakaryocytes (large bone marrow cells), analyzed from a simple blood test may be able to target men with aggressive prostate cancer that has spread (metastasized), according to a small study (Xu et al) by researchers at Queen Mary University of London. The researchers looked at blood samples from 81 men with prostate cancer. The results hold promise for determining men with prostate cancer who might benefit from aggressive therapy. The next step will be larger clinical trials. The results of the study were published in Clinical Cancer Research.July 7, 2017.
Liberating Research is looking for men living with prostate cancer (metastatic or recurrent) to help understand their perspective on diagnosis and treatment. There are two ways to participate if you live in New York, Los Angeles, or San Francisco: via telephone or in a face-to-face interview. Your opinions will help improve future educational materials for healthcare practitioners. If eligible, you will be paid for your participation (10% goes to a charity). Time is limited. Make your voice known! May 19, 2017.
Researchers have been able to cure invasive prostate cancer in mice using an existing anticancer drug (cabozantinib). The drug worked by encouraging prostate cancer tumor cells to secrete substances that attracted neutrophils—which are produced in the bone marrow—to enter the tumor and created an immune response that led to an almost complete clearance of tumors, according to a ScienceDaily report. Let’s hope that the drug works just as well in humans some day. Clinical trials are planned to assess using cabozantinib in combination with T-cell immunotherapy for prostate cancer. May 9, 2017.
Researchers (Matthew et al) are hopeful that a triple combination of hormone therapy, surgery, and radiation may be able to eliminate detectable disease in some men with metastatic prostate cancer. In a very small pilot study, 20 men were treated with androgen deprivation therapy, radical prostatectomy, and radiation treatment. Of that number, 14 men who had prostate cancer metastases to the bone had undetectable PSA for up to 46 months following all 3 treatments. While this is optimistic news for men with metastatic prostate cancer, a larger clinical trial is needed to confirm the findings. April 25, 2017.
Researchers at Washington State University are exploring a noninvasive device that analyzes blood and urine to help diagnose prostate cancer and assess extent of disease progression. The device is like a filter that isolates markers of prostate cancer from blood and urine. It uses a mat of tiny glass springs that contain biomarkers that attract exosomes; fatty droplets of proteins and RNA that prostate cancer tumors release into body fluids (like blood and urine) and contain useful genetic information. It is still in the early research phase, but it would be a welcome alternative to biopsy, which can be a very uncomfortable procedure for men. March 28, 2017.
An antidepressant called clorgyline may block an enzyme called MAOA that helps prostate cancer cells spread to the bone, according to a new animal (mouse) study (Wu et al) that was published in Cancer Cell. While clorgyline is no longer used by doctors, researchers will begin studying other antidepressants that have a similar mechanism of action. March 20, 2017.
Always consult a medical professional.